Close Menu

Ginkgo Bioworks

The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

Ginkgo said that next-generation sequencing, coupled with its automation capabilities, has the potential to increase COVID-19 testing capacity.

Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.

Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.

Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.

Ginkgo will acquire Beacon optofluidic platforms from Berkeley Lights and incorporate them into its automated genetic engineering foundries.

Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.

The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.

About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.

In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.